Fresenius SE is a healthcare holding company based in Germany... Show more
FSNUF saw its Momentum Indicator move above the 0 level on July 30, 2025. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 45 similar instances where the indicator turned positive. In of the 45 cases, the stock moved higher in the following days. The odds of a move higher are at .
The Moving Average Convergence Divergence (MACD) for FSNUF just turned positive on August 14, 2025. Looking at past instances where FSNUF's MACD turned positive, the stock continued to rise in of 30 cases over the following month. The odds of a continued upward trend are .
FSNUF moved below its 50-day moving average on August 01, 2025 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for FSNUF crossed bearishly below the 50-day moving average on August 01, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
The Aroon Indicator for FSNUF entered a downward trend on August 19, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.223) is normal, around the industry mean (9.881). P/E Ratio (19.656) is within average values for comparable stocks, (116.890). Projected Growth (PEG Ratio) (0.382) is also within normal values, averaging (2.108). Dividend Yield (0.024) settles around the average of (0.039) among similar stocks. P/S Ratio (1.004) is also within normal values, averaging (1.642).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. FSNUF’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FSNUF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry HospitalNursingManagement